RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS

Introduction. The anthracycline antibiotics cause clinically significant manifestations of cardiotoxicity (СТ) – myocardial injuries, reducing both quality and life expectancy of the oncological patients.

The purpose of the study was to evaluate the incidence and risk factors anthracycline-induced СТ in patients with hemoblastosis.

Materials and methods. The study included 131 case histories of patients with hemoblastosis, treated with anthracyclines. Patients were divided into two groups according to age – the 1st group involved 77 patients aged from 18 up to 50 years (average age of 25.6 ± 3.4 years), the 2nd – 54 patients aged from 51 up to 75 years (average age of 56.8 ± 4.6 years). At the first investigation phase we studied the incidence of anthracycline-induced СТ in various age groups patients. The second phase devoted to studying potential risk factors (a cumulative dose more than 240 mg/m², a female, an age, the accompanying application of mediastinal radiation therapy or other cardiotoxic drugs, cardioprotection absence) influence on anthracycline-induced CD frequency.

Results. The incidence of CT in young patients was 38.2% (95% confidence interval (CI) 25.6–51.6%), among the older age group – 14.3% (95% CI 5.3–26.7%). The incidence of CT is significantly higher among young people (χ²  = 5.63, p = 0.018). According to the results of univariate regression analysis, significant risk factors for the development of myocardial damage in patients with CT signs were: age <50 years – the odds ratio (OR) 2.69; 95% CI 1.05–6.84; the cumulative anthracycline dose more than 240 mg/m²  by doxorubicin (OR 5.17, 95% CI 1.38–27.55)  and the absence of prophylactic cardioprotective therapy (OR 23.38, 95% CI 6.49–84.14 ). In multivariate regression analysis independent risk factors for myocardial damage development were only the cumulative anthracyclines dose more than 240 mg/m²  (OR 6.17, 95% CI 1.32–28.71)  and the absence of prophylactic cardioprotective therapy (OR 2.82, 95% CI 1.09–7.28).

Conclusions. Statistically significant higher anthracycline-induced cardiotoxicity frequency appeared in young patients. Reliable (р <0.05) cardiotoxicity risk factors were cumulative dose more than 240 mg/m²  and cardioprotection absence.

1. Zamorano J.L., Lancellotti P., Muñoz D.R. et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016;37(36):2768–801. DOI: 10.1093/eurheartj/ehw211. PMID: 27567406.

2. Curigliano G., Cardinale D., Suter T. et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 2012;23:155–66. DOI: 10.1093/an-nonc/mds293. PMID: 22997448.

3. Снеговой А.В., Виценя М.В., Копп М.В. и др. Практические рекомендации по коррекции кардиоваскулярной токсичности, индуцированной химиотерапией и таргетными препаратами. Злокачественные опухоли 2015;4:369–78. [Snegovoy A.V., Vitsenya M.V., Kopp M.V. et al. Practical recommendations for the correction of cardiovascular toxicity induced by chemotherapy and targeted drugs. Zlokachestvennye opukholi = Malignant tumors 2015;4:369–78 (In Russ.)]. DOI: 10.18027/2224-5057-2016-4s2-418-427.

4. Калинкина Н.В. Повреждение сердца антрациклинами. Донецк: Каштан, 2008. [Kalinkina N.V. Heart damage by anthracyclines. Kaschtan: Donetsk, 2008. (In Russ.)].

5. Селиверстова Д.В., Евсина О.В. Кардиотоксичность химиотерапии. Сердце: журнал для практикующих врачей 2016;15(1):50–7. [Seliverstova D.V., Evsina O.V. Cardiotoxicity of chemotherapy. Serdtse: Zhurnal dlya praktikuyushchich vrachey = Russian Heart Journal 2016;15(1):50–7 (In Russ.)]. DOI: 10.18087/rhj.2016.1.2115.

6. Гендлин Г.Е., Емелина Е.И., Никитин И.Г. и др. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал 2017;3(143):145–54. [Gendlin G.E., Emelina E.I., Nikitin I.G. et al. Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology 2017;3(143):145–54 (In Russ.)]. DOI: 10.15829/1560-4071-2017-3-145-154.

7. Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22(4):263–302. PMID: 10789823.

8. Manrique С.R., Park M., Tiwari N. et al. Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. Clin Med Insights Cardiol 2017;11:1–12. DOI: 10.1177/1179546817697. PMID: 28469492.

9. Senkus E., Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011;37(4):300–11. DOI: 10.1016/j.ctrv.2010.11.001. PMID: 21126826.

10. Yeh E.T., Tong A.T., Lenihan D.J. et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109(25):3122–31. DOI: 10.1161/01.CIR.0000133187.74800.B9. PMID: 15226229.

11. Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34(15):1102–11. DOI: 10.1093/eurheartj/ehs181. PMID: 22789916.

12. Miolo G.M., La Mura N., Nigri P. et al. The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiol Oncol 2006;40(3): 149–61.

13. Volkova M., Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011;7(4):214–20. DOI: 10.2174/157340311799960645. PMID: 22758622.